{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:26:34Z","timestamp":1759177594339},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T00:00:00Z","timestamp":1498521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00280-017-3363-0","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T11:47:34Z","timestamp":1498564054000},"page":"355-361","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)"],"prefix":"10.1007","volume":"80","author":[{"given":"Tadahiro","family":"Shoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Omi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kagabu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Futagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kaiho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Kojimahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Watanebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,27]]},"reference":[{"key":"3363_CR1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jjco\/hyq192","volume":"41","author":"D Aoki","year":"2011","unstructured":"Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K, Kamiura S, Hiura M, Hatae M, Sugiyama T, Ochiai K, Noda K (2011) A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol 41:320\u2013327","journal-title":"Jpn J Clin Oncol"},{"key":"3363_CR2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jjco\/hyn101","volume":"38","author":"N Katsumata","year":"2008","unstructured":"Katsumata N, Fujiwara Y, Kamura T, Nakanishi T, Hatae M, Aoki D, Tanaka K, Tsuda H, Kamiura S, Takehara K, Sugiyama T, Kigawa J, Fujiwara K, Ochiai K, Ishida R, Inagaki M, Noda K (2008) Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a phase II study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol 38:777\u2013785","journal-title":"Jpn J Clin Oncol"},{"key":"3363_CR3","first-page":"4029","volume":"32","author":"K Yoshino","year":"2012","unstructured":"Yoshino K, Hiramatsu K, Enomoto T, Fujita M, Ueda Y, Kimura T, Kobayashi E, Kiyohara Y, Tsutsui T, Kimura T (2012) Salvage chemotherapy using gemcitabine for taxane\/platinum-resistant recurrent ovarian cancer: a single institutional experience. Anticancer Res 32:4029\u20134033","journal-title":"Anticancer Res"},{"key":"3363_CR4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"3363_CR5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","volume":"100","author":"K Matsumoto","year":"2006","unstructured":"Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M, Fujiwara Y (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100:412\u2013416","journal-title":"Gynecol Oncol"},{"key":"3363_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0304-3835(98)00065-2","volume":"128","author":"T Sugiyama","year":"1998","unstructured":"Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J, Terakawa N (1998) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128:211\u2013218","journal-title":"Cancer Lett"},{"key":"3363_CR7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-014-2418-8","volume":"73","author":"T Shoji","year":"2014","unstructured":"Shoji T, Takatori E, Kaido Y, Omi H, Yokoyama Y, Mizunuma H, Kaiho M, Otsuki T, Takano T, Yaegashi N, Nishiyama H, Fujimori K, Sugiyama T (2014) A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol 73:895\u2013901","journal-title":"Cancer Chemother Pharmacol"},{"key":"3363_CR8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2007.03.036","volume":"106","author":"S Nishio","year":"2007","unstructured":"Nishio S, Sugiyama T, Shouji T, Yoshizaki A, Kitagawa R, Ushijima K, Kamura T (2007) Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 106:342\u2013347","journal-title":"Gynecol Oncol"},{"key":"3363_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/IGC.0b013e3181ffbe9f","volume":"21","author":"T Shoji","year":"2011","unstructured":"Shoji T, Takatori E, Omi H, Kumagai S, Yoshizaki A, Yokoyama Y, Mizunuma H, Fujimoto T, Takano T, Yaegashi N, Tase T, Nakahara K, Kurachi H, Nishiyama H, Sugiyama T (2011) Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). Int J Gynecol Cancer 21:44\u201350","journal-title":"Int J Gynecol Cancer"},{"key":"3363_CR10","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818","journal-title":"J Clin Oncol"},{"key":"3363_CR11","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093\u20133100","journal-title":"J Clin Oncol"},{"key":"3363_CR12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"3363_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852\u2013861","journal-title":"Lancet Oncol"},{"key":"3363_CR14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","volume":"15","author":"BJ Monk","year":"2014","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomm\u00e9 C, Richardson G, Rinc\u00f3n DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:799\u2013808","journal-title":"Lancet Oncol"},{"key":"3363_CR15","doi-asserted-by":"crossref","unstructured":"Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A (2015) Pazopanib maintenance therapy in East Asian Women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer (epub ahead of print)","DOI":"10.1097\/IGC.0000000000000602"},{"key":"3363_CR16","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015\u20134022","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3363-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3363-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T06:28:02Z","timestamp":1501136882000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3363-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,27]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3363-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,27]]}}}